• EQRx signs $1.8bn merger deal with CM Life Sciences III pharmaceutical-technology
    August 10, 2021
    Pharmaceutical company EQRx and a life science-focused special purpose acquisition company (SPAC), CM Life Sciences III, have signed a definitive business combination agreement worth up to $1.8bn.
PharmaSources Customer Service